The Experts below are selected from a list of 5649 Experts worldwide ranked by ideXlab platform
Sergio Fazio - One of the best experts on this subject based on the ideXlab platform.
-
discordant responses of plasma low density lipoprotein cholesterol and lipoprotein a to alirocumab a pooled analysis from 10 odyssey phase 3 studies
European Journal of Preventive Cardiology, 2021Co-Authors: Tahir Mahmood, Sergio Fazio, Jessica Minnier, Matthew K Ito, Andrew Koren, Ivy W Kam, Michael D ShapiroAbstract:AimsProprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors consistently reduce low-density lipoprotein cholesterol (LDL-C) by 50–60% and lipoprotein(a) (Lp(a)) by 20–30%, but the mechanis...
-
lipoprotein a pcsk9 inhibition and cardiovascular risk
Circulation, 2019Co-Authors: Michelle L Odonoghue, Richard Ceska, Scott M Wasserman, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouniberthold, Armando Lira Pineda, M V EzhovAbstract:Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/Kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concen...
-
relationship between low density lipoprotein cholesterol and lipoprotein a lowering in response to pcsk9 inhibition with evolocumab
Journal of the American Heart Association, 2019Co-Authors: Michael D Shapiro, Ransi Somaratne, Hagai Tavori, Jessica Minnier, Helina Kassahun, Andrea Flower, Sergio FazioAbstract:Background Beyond their potent LDL (low‐density lipoprotein) cholesterol (LDL‐C)–lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/Kexin type 9) inhibitors also reduce Lp(a) (lipo...
-
serum proprotein convertase subtilisin Kexin type 9 and cell surface low density lipoprotein receptor evidence for a reciprocal regulation
Circulation, 2013Co-Authors: Hagai Tavori, Daping Fan, John L Blakemore, Patricia G Yancey, Lei Ding, Macrae F Linton, Sergio FazioAbstract:Background—Proprotein convertase subtilisin/Kexin type 9 (PCSK9) modulates low-density lipoprotein (LDL) receptor (LDLR) degradation, thus influencing serum cholesterol levels. However, dysfunction...
Wouter J Jukema - One of the best experts on this subject based on the ideXlab platform.
-
peripheral artery disease and venous thromboembolic events after acute coronary syndrome role of lipoprotein a and modification by alirocumab prespecified analysis of the odyssey outcomes randomized clinical trial
Circulation, 2020Co-Authors: Gregory G Schwartz, Philippe Gabriel Steg, Michael Szarek, Vera Bittner, Rafael Diaz, Shaun G Goodman, Yongun Kim, Wouter J JukemaAbstract:Background: Patients with acute coronary syndrome are at risk for peripheral artery disease (PAD) events and venous thromboembolism (VTE). PCSK9 (proprotein convertase subtilisin/Kexin type 9) inhi...
-
low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease insights from the fourier trial further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk
Circulation, 2017Co-Authors: Marc P Bonaca, Robert P Giugliano, Estella Kanevsky, Armando Lira Pineda, Patrice Nault, Anthony C Keech, Julia Kuder, Sabina A Murphy, Wouter J Jukema, Basil S LewisAbstract:Background:The PCSK9 (proprotein convertase subtilisin/Kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiov...
Robert P Giugliano - One of the best experts on this subject based on the ideXlab platform.
-
stroke prevention with the pcsk9 proprotein convertase subtilisin Kexin type 9 inhibitor evolocumab added to statin in high risk patients with stable atherosclerosis
Stroke, 2020Co-Authors: Robert P Giugliano, Scott M Wasserman, Anthony C Keech, Sabina A Murphy, Peter S Sever, Terje R Pedersen, Jeffrey L Saver, Erin A Bohula, Narimon Honarpour, Huei WangAbstract:Background and Purpose— The PCSK9 (proprotein convertase subtilisin-Kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and...
-
lipoprotein a pcsk9 inhibition and cardiovascular risk
Circulation, 2019Co-Authors: Michelle L Odonoghue, Richard Ceska, Scott M Wasserman, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouniberthold, Armando Lira Pineda, M V EzhovAbstract:Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/Kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concen...
-
clinical benefit of evolocumab by severity and extent of coronary artery disease analysis from fourier
Circulation, 2018Co-Authors: Marc S Sabatine, Robert P Giugliano, Julia Kuder, Sabina A Murphy, Basil S Lewis, Gaetano M De Ferrari, Kurt Huber, Jorge Ferreira, Stephen D Wiviott, Christopher E KurtzAbstract:Background: The FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk) recently showed that the PCSK9 (proprotein convertase subtilisin-Kexin ...
-
comparison of ldl c reduction using different evolocumab doses and intervals biological insights and treatment implications
Journal of Cardiovascular Pharmacology and Therapeutics, 2018Co-Authors: Scott M Wasserman, Ransi Somaratne, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Jason C Legg, Maurice Emery, Sameer Doshi, John P GibbsAbstract:Background:The proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitor evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of cardiovascular events.Objectives:To com...
-
low density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease insights from the fourier trial further cardiovascular outcomes research with pcsk9 inhibition in subjects with elevated risk
Circulation, 2017Co-Authors: Marc P Bonaca, Robert P Giugliano, Estella Kanevsky, Armando Lira Pineda, Patrice Nault, Anthony C Keech, Julia Kuder, Sabina A Murphy, Wouter J Jukema, Basil S LewisAbstract:Background:The PCSK9 (proprotein convertase subtilisin/Kexin type 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the FOURIER trial (Further Cardiov...
Michael D Shapiro - One of the best experts on this subject based on the ideXlab platform.
-
hepatic sensing loop regulates pcsk9 secretion in response to inhibitory antibodies
Journal of the American College of Cardiology, 2021Co-Authors: Carlota Oleaga, Peter P Toth, Hagai Tavori, Michael D Shapiro, Joshua Hay, Paul Mueller, Joshua Miles, Cecilia Huang, Emily Friz, Cezary WojcikAbstract:Abstract Background Monoclonal antibodies against proprotein convertase subtilisin/Kexin type 9 (PCSK9i) lower LDL-C by up to 60% and increase plasma proprotein convertase subtilisin/Kexin type 9 (...
-
discordant responses of plasma low density lipoprotein cholesterol and lipoprotein a to alirocumab a pooled analysis from 10 odyssey phase 3 studies
European Journal of Preventive Cardiology, 2021Co-Authors: Tahir Mahmood, Sergio Fazio, Jessica Minnier, Matthew K Ito, Andrew Koren, Ivy W Kam, Michael D ShapiroAbstract:AimsProprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors consistently reduce low-density lipoprotein cholesterol (LDL-C) by 50–60% and lipoprotein(a) (Lp(a)) by 20–30%, but the mechanis...
-
future role of proprotein convertase subtilisin Kexin type 9 inhibitors in preventive cardiology
Current Opinion in Cardiology, 2019Co-Authors: Tahir Mahmood, Michael D ShapiroAbstract:Purpose of reviewThe use of therapeutic monoclonal antibodies to target proprotein convertase subtilisin/Kexin type 9 (PCSK9) represents a novel approach to the management of hypercholesteremia and prevention of atherosclerotic cardiovascular disease. We review the most recent literature relevant to
-
relationship between low density lipoprotein cholesterol and lipoprotein a lowering in response to pcsk9 inhibition with evolocumab
Journal of the American Heart Association, 2019Co-Authors: Michael D Shapiro, Ransi Somaratne, Hagai Tavori, Jessica Minnier, Helina Kassahun, Andrea Flower, Sergio FazioAbstract:Background Beyond their potent LDL (low‐density lipoprotein) cholesterol (LDL‐C)–lowering efficacy (50–60%), PCSK9 (proprotein convertase subtilisin/Kexin type 9) inhibitors also reduce Lp(a) (lipo...
Scott M Wasserman - One of the best experts on this subject based on the ideXlab platform.
-
stroke prevention with the pcsk9 proprotein convertase subtilisin Kexin type 9 inhibitor evolocumab added to statin in high risk patients with stable atherosclerosis
Stroke, 2020Co-Authors: Robert P Giugliano, Scott M Wasserman, Anthony C Keech, Sabina A Murphy, Peter S Sever, Terje R Pedersen, Jeffrey L Saver, Erin A Bohula, Narimon Honarpour, Huei WangAbstract:Background and Purpose— The PCSK9 (proprotein convertase subtilisin-Kexin type 9) monoclonal antibody evolocumab lowered LDL (low-density lipoprotein) cholesterol by 59% to 0.8 (0.5–1.2) mmol/L and...
-
lipoprotein a pcsk9 inhibition and cardiovascular risk
Circulation, 2019Co-Authors: Michelle L Odonoghue, Richard Ceska, Scott M Wasserman, Sergio Fazio, Robert P Giugliano, Erik S G Stroes, Estella Kanevsky, Ioanna Gouniberthold, Armando Lira Pineda, M V EzhovAbstract:Background: Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/Kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concen...
-
comparison of ldl c reduction using different evolocumab doses and intervals biological insights and treatment implications
Journal of Cardiovascular Pharmacology and Therapeutics, 2018Co-Authors: Scott M Wasserman, Ransi Somaratne, Robert P Giugliano, Marc S Sabatine, Michael J Koren, Jason C Legg, Maurice Emery, Sameer Doshi, John P GibbsAbstract:Background:The proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitor evolocumab reduces low-density lipoprotein cholesterol (LDL-C) and the risk of cardiovascular events.Objectives:To com...
-
levels of non high density lipoprotein cholesterol do not negatively impact the ability of the pcsk9 inhibitor evolocumab to promote regression of coronary atherosclerosis
Journal of the American College of Cardiology, 2018Co-Authors: Adam J Nelson, Ransi Somaratne, Scott M Wasserman, Christie M Ballantyne, Helina Kassahun, Rishi Puri, Danielle M Brennan, Steven E Nissen, Stephen J NichollsAbstract:Levels of non-HDL-C reflect the total circulating pool of atherogenic lipid factors and have been associated with ongoing plaque progression on statin treatment. It is unknown whether these levels modulate the degree of regression observed with addition of a proprotein convertase subtilisin Kexin
-
sex related difference in the regression of coronary atherosclerosis with the pcsk9 inhibitor evolocumab insights from glagov
Journal of the American College of Cardiology, 2018Co-Authors: Peta King, Ransi Somaratne, Scott M Wasserman, Christie M Ballantyne, Helina Kassahun, Rishi Puri, Danielle M Brennan, Steven E Nissen, Stephen J NichollsAbstract:The proprotein convertase subtilisin Kexin type 9 (PCSK9) inhibitor, evolocumab, promotes regression of coronary atherosclerosis in statin-treated patients. It is unknown whether there are gender related differences in this treatment effect. GLAGOV compared the effects of treatment for 78 weeks